News | August 08, 2024
JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr
Expect the international business including CDMO business to pick-up in the second half of the financial year
Expect the international business including CDMO business to pick-up in the second half of the financial year
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Revolutionary technology will further boost OneSource’s scientific services offerings
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Shivani Satish Wagh takes on the role of Joint Managing Director
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Strong topline growth driven by solid performance across key brands.
Subscribe To Our Newsletter & Stay Updated
